Studies investigating if NGS can simultaneously output SMN2 copy number in SMA positive screens may be useful to clinicians because SMN2 copy number is used to guide early treatment of SMA, thereby improving the clinical utility of NGS assays for SMA screening. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.